Neuroendocrine tumours trials in Italy

In Italy 25 Also abroad 244

25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Bologna, Brescia, Milan, Naples, Siena, Verona
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Where
Bari, Florence, Milan, Naples, Palermo, Rome, Verona
Age
18 years and over
People
390 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00
Phase 2/3Taking people
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Where
Aviano, Bologna, Meldola, Milan, Naples, Orbassano to, Palermo, Roma
Age
18 years and over
People
440 worldwide
Run by
Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00
No phaseTaking people
Multicenter Study for External Validation of the TB-NET Score
Where
Milan
Age
18 years and over
People
400 worldwide
Run by
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
See details and how to joinNCT07903532
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Milan, Naples
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Ferrara, Genoa, Milan, Negrar, Pisa, Rome, Rozzano
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00
No phaseTaking people
Iconographic Registry of Pancreatobiliary Endoscopy Procedures
Where
Milan
Age
18 years and over
People
12,000
Run by
IRCCS San Raffaele
See details and how to joinNCT06344507
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Bari, Bergamo, Meldola, Milan, Rome, Verona
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Ancona, Brescia, Candiolo, Milan, Parma, Rome
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 3Taking people
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Where
Bari, Meldola, Milan, Reggio Emilia, Roma, Verona
Age
18 years and over
People
170 worldwide
Run by
Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00
Phase 2Not yet taking people in Italy
Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial
Where
Cesena, Meldola
Age
18 years and over
People
178
Run by
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
See details and how to join2024-519183-40-00 · EU 2024-519183-40-00
No phaseTaking people
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Where
Milan
People
34
Run by
European Institute of Oncology
See details and how to joinNCT07429851
No phaseTaking people
Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
Where
Milan
Age
18 years and over
People
450
Run by
IRCCS San Raffaele
See details and how to joinNCT06356467
No phaseTaking people
Development of New Personalised 3D Preclinical Models of Pancreatic Neuroendocrine Tumours
Where
Milan
Age
18 years and over
People
70
Run by
IRCCS San Raffaele
See details and how to joinNCT06121622
No phaseTaking people
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Where
Rome
Age
18 years to 80 years
People
60
Run by
University of Roma La Sapienza
See details and how to joinNCT04464122
No phaseTaking people
Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel
Where
Milan
Age
18 years and over
People
18
Run by
European Institute of Oncology
See details and how to joinNCT06773624
Phase 2Taking people
Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study
Where
Milan
Age
18 years and over
People
46
Run by
European Institute of Oncology
See details and how to joinNCT05554003
Phase 2Taking people
A Phase II trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET): The LOLA trial
Where
Bari, Bologna, Brescia, Milan, Naples, Orbassano, Rome, Rozzano, Verona, Viagrande
Age
18 years and over
People
69
Run by
Fondazione IRCCS Istituto Nazionale Dei Tumori
See details and how to join2024-516612-16-00 · EU 2024-516612-16-00
Phase 2Taking people
A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.
Where
Meldola
Age
18 years and over
People
51
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT04166006 · EU 2023-510251-31-00
Phase 2Taking people
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
Where
Cesena, Meldola
Age
18 years and over
People
100
Run by
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
See details and how to joinNCT06045260
Phase 2Taking people
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)
Where
Naples
Age
18 years and over
People
35
Run by
National Cancer Institute, Naples
See details and how to joinNCT04893785
Phase 2Taking people
Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)
Where
Aviano, Bari, Bologna, Florence, Lucca, Meldola, Monza, Naples, Orbassano, Padova, Parma, Roma, Rozzano, Sassari, Viagrande
Age
18 years and over
People
49
Run by
Gruppo Oncologico Italiano di Ricerca Clinica
See details and how to joinNCT06418087
No phaseTaking people
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
Where
Milan
Age
18 years to 39 years
People
90
Run by
European Institute of Oncology
See details and how to joinNCT06337760
No phaseTaking people
Protocol ITANET - Registry
Where
Ancona, Bari, Bologna, Bolzano, Brescia, Brindisi, Catania, Ferrara, Genova, Latina, Messina, Milan, Modena, Monza, Naples, Padova, Palermo, Peschiera del Garda, Pisa, Reggio Emilia, Rho, Roma, Rome, Rozzano, San Giovanni Rotondo, Sassari, Siena, Torino, Trento, Verona
Age
18 years and over
People
3,600
Run by
Italian Association Neuroendocrine Tumors
See details and how to joinNCT04282083
No phaseTaking people
68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine Tumours
Where
Milan
Age
18 years and over
People
300
Run by
IRCCS San Raffaele
See details and how to joinNCT06155318